Clinical Trial Update: Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for masitinib in relapse/refractory multiple myeloma with t(4/14) translocation, FGFR3 expression status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Masitinib (masitinib)

Snippet

Sponsor: AB Science | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED